{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-26-000047","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2026-06-30T12:05:11+00:00","discovered_at":"2026-06-30T12:10:00.407355+00:00","generated_at":"2026-06-30T12:10:31.217540+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"VOICE trial interim analysis shows Vafseo superior to ESA on composite endpoint; trial stopped","bullets":["Win odds 1.16 (95% CI 1.06-1.28, p=0.0016) for all-cause mortality/hospitalization composite.","Hospitalizations per patient-year: 1.11 (Vafseo) vs 1.23 (ESA); incidence rate ratio 0.90 (p<0.05).","Mortality rates similar: 8.77% vs 8.78% per 100 patient-years; rate ratio 1.00 (CI 0.718-1.391).","Trial stopped on recommendation of Independent Data Monitoring Committee and Trial Steering Committee.","Results replicate safety findings from INNO2VATE phase 3 program; data to be submitted for scientific meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-26-000047","json":"https://secwatch.observer/filing/0001517022-26-000047.json","markdown":"https://secwatch.observer/filing/0001517022-26-000047.md","text":"https://secwatch.observer/filing/0001517022-26-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/0001517022-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/akba-20260630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T12:10:31.217540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}